{'52WeekChange': None,
 'SandP52WeekChange': None,
 'address1': '100 Technology Center Drive',
 'address2': 'Suite 300',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 18.49,
 'askSize': 1400,
 'averageDailyVolume10Day': 269025,
 'averageVolume': 420909,
 'averageVolume10days': 269025,
 'beta': 1.05098,
 'beta3Year': None,
 'bid': 15.51,
 'bidSize': 1400,
 'bookValue': 4.112,
 'category': None,
 'circulatingSupply': None,
 'city': 'Stoughton',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 17.34,
 'dayLow': 16.62,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': 56.419,
 'enterpriseToRevenue': 2.533,
 'enterpriseValue': 756528256,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 17.573572,
 'fiftyTwoWeekHigh': 25.59,
 'fiftyTwoWeekLow': 10.01,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 29968145,
 'forwardEps': 1.7,
 'forwardPE': 9.864706,
 'fromCurrency': None,
 'fullTimeEmployees': 255,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.01998,
 'heldPercentInstitutions': 1.06741,
 'industry': 'Drug Manufacturers—Specialty & Generic',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/collegiumpharma.com',
 'longBusinessSummary': 'Collegium Pharmaceutical, Inc., a specialty '
                        'pharmaceutical company, develops and commercializes '
                        'various products for patients suffering from pain. It '
                        'provides DETERx platform technology that is designed '
                        'to maintain the extended-release and safety profiles '
                        'of highly abused drugs in the face of various methods '
                        'of abuse and misuse, including chewing, crushing, '
                        'heating, and injecting. The company offers Xtampza '
                        'ER, an abuse-deterrent, extended-release, oral '
                        'formulation of oxycodone for opioid medication. '
                        'Furhter, it offers Nucynta ER, an extended release '
                        'formulation of tapentadol for the management of pain '
                        'severe enough to require daily, around-the-clock, '
                        'long term opioid treatment, such as neuropathic pain '
                        'related to diabetic peripheral neuropathy in adults; '
                        'and Nucynta IR, an immediate release formulation of '
                        'tapentadol that is indicated for the management of '
                        'moderate to severe acute pain in adults. The company '
                        'was formerly known as Collegium Pharmaceuticals, Inc. '
                        'and changed its name to Collegium Pharmaceutical, '
                        'Inc. in October 2003. Collegium Pharmaceutical, Inc. '
                        'was incorporated in 2002 and is headquartered in '
                        'Stoughton, Massachusetts.',
 'longName': 'Collegium Pharmaceutical, Inc.',
 'market': 'us_market',
 'marketCap': 575814720,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_7490189',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -12572000,
 'nextFiscalYearEnd': 1640908800,
 'open': 16.9,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 41.53,
 'phone': '781 713 3699',
 'previousClose': 16.9,
 'priceHint': 2,
 'priceToBook': 4.0783076,
 'priceToSalesTrailing12Months': 1.9277618,
 'profitMargins': -0.042090002,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 17.34,
 'regularMarketDayLow': 16.62,
 'regularMarketOpen': 16.9,
 'regularMarketPreviousClose': 16.9,
 'regularMarketPrice': 16.9,
 'regularMarketVolume': 178917,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 34336000,
 'sharesPercentSharesOut': 0.1364,
 'sharesShort': 4684121,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4430678,
 'shortName': 'Collegium Pharmaceutical, Inc.',
 'shortPercentOfFloat': 0.1591,
 'shortRatio': 9.82,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'COLL',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.378,
 'twoHundredDayAverage': 19.725756,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'ce084fc3-381a-311e-a750-8eb7c247886f',
 'volume': 178917,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.collegiumpharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02072'}